LAG-3 antagonists for cancer treatment: an updated patent review (2020-2025) [0.03%]
癌症治疗的LAG-3拮抗剂专利回顾（2020-2025）
Martín Pérez-Santos,Gerardo Landeta,Maricruz Anaya-Ruiz et al.
Martín Pérez-Santos et al.
Introduction: LAG-3 is a molecule overexpressed on the surface of CD4+ and CD8+ cells in the tumor microenvironment that prevents T-cell activation and production of IL-2 and IFN-γ. ...
A patent review of KDM4 histone demethylase inhibitors (2014-present) [0.03%]
2014年至今KDM4组蛋白去甲基酶抑制剂专利分析
Xiaolong Yang,Yuyan Han,Lei Yu et al.
Xiaolong Yang et al.
Introduction: The KDM4 family of histone demethylases, characterized by a conserved JmjC catalytic domain, comprises six subtypes: KDM4A - F. Aberrant expression of these enzymes has been associated with tumorigenesis acr...
Eleonora Boccia,Stefania Terracciano,Maria Giovanna Chini et al.
Eleonora Boccia et al.
Introduction: Bromodomain-containing protein 9 (BRD9) is an epigenetic reader component of the non-canonical BAF (BRG1/BRM-Associated Factors) chromatin remodeling complex, involved in the regulation of transcription. The...
Impact of patent-granting differences between Japan and the United States on patent protection for medical methods: insights from genome editing patents [0.03%]
日本与美国专利授予差异对医药方法专利保护之影响——以基因编辑技术专利为例分析
Toru Matsuoka,Shingo Kano
Toru Matsuoka
Introduction: Securing patents in multiple countries has become essential for the development of global medical products. However, differences in national patent systems result in varying patentability standards. Although...
An updated patent review of acetylcholinesterase inhibitors for the treatment of alzheimer's disease (2021 - present) [0.03%]
2021年以来阿尔茨海默病治疗乙酰胆碱酯酶抑制剂类药物专利综述更新
Paloma Begines,José G Fernández-Bolaños,Óscar López
Paloma Begines
Introduction: Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with a complex and not fully elucidated etiology. An exponential rise in its incidence underscores the urgent need for effective therap...
Tricyclic boronic acids as broad-spectrum serine and metallo-β-lactamase inhibitors with in vitro activity against acinetobacter baumannii: a patent evaluation (us 2025/0223303) [0.03%]
三环硼酸类化合物作为广谱丝氨酸和金属-β-内酰胺酶抑制剂对体外分枝杆菌活性的专利评估（US 2025/0223303）
Alen Krajnc
Alen Krajnc
Introduction: With β-lactams remaining the most widely prescribed antibacterials worldwide, their continuing clinical efficacy remains an important therapeutic goal. Rapid spread of serine and metallo-ß-lactamases (SBLs...
Lysine demethylase (KDM) inhibitors for the treatment of cancer: a patent review (2015-present) [0.03%]
组蛋白去甲基化酶(KDM)抑制剂在癌症治疗中的应用专利点评(2015-至今)
Federica Sarno,Mariarosaria Conte,Annamaria Muro et al.
Federica Sarno et al.
Introduction: Lysine demethylases (KDMs) are crucial epigenetic regulators that modulate gene expression via demethylation of histone and non-histone proteins, playing a pivotal role in cancer progression. Dysregulation o...
Coactivator-associated arginine methyltransferase 1 (CARM1) inhibitors: a patenting perspective (2018-present) [0.03%]
CARM1抑制剂专利透视（2018-今）
Monica Viviano,Alessandra Cipriano,Alessandra Feoli et al.
Monica Viviano et al.
Introduction: CARM1 (Coactivator-associated arginine methyltransferase 1), also known as PRMT4 (Protein Arginine Methyltransferase 4), is a type I PRMT that regulates gene expression by methylating both histone and non-hi...
A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 - present) [0.03%]
2020年至今Mpro蛋白酶抑制剂治疗COVID-19的专利审查
Václav Mik,Laila S Benz,Jiří Voller et al.
Václav Mik et al.
Introduction: The SARS-CoV-2 main protease (Mpro, also known as 3CLpro or nsp5) is essential for viral replication. As there are no close human homologs, it represents an attractive and specific target for antiviral thera...
Patent landscape in hydroxamic acid-based HDAC inhibitors (2020-2024): structure-activity relationships and mechanistic insights [0.03%]
基于羟胺酸的HDAC抑制剂（2020-2024）专利图谱：结构-活性关系及机制见解
Ekta Shirbhate,Vaibhav Singh,Vidya Prabha et al.
Ekta Shirbhate et al.
Introduction: The hydroxamic acid-based histone deacetylase (HDAC) inhibitors play a crucial role as anticancer chemotherapeutics. It controls cellular pathways and epigenetically modify gene expression, making them impor...